Psoriatic arthritis (PsA) — peripheral, axial, enthesitis & dactylitis
Bedside summary
Seronegative inflammatory arthritis associated with psoriasis (skin psoriasis precedes arthritis in ~70%, but ~15% arthritis-first). Heterogeneous domains: peripheral arthritis (asymmetric oligoarthritis or symmetric polyarthritis, DIP involvement), axial disease (sacroiliitis/spondylitis), enthesitis (Achilles, plantar fascia), dactylitis ('sausage digit'), nail disease (pitting, onycholysis). Part of the spondyloarthritis family; HLA-B27 associated with axial disease. Can be erosive/mutilating. Managed by domain-based treatment escalation (GRAPPA/EULAR).
Red flags
- Painful red eye + photophobia — anterior uveitis (urgent ophthalmology)
- Arthritis mutilans — rapidly destructive, telescoping digits (aggressive early biologic)
- New/worsening GI symptoms on IL-17 inhibitor — may unmask/flare inflammatory bowel disease
- Hot single joint with fever — exclude septic arthritis (aspirate)
- Inflammatory back pain with neurology — advanced axial disease/fracture through ankylosed spine
Assessment
Differential diagnosis
- Rheumatoid arthritis (symmetric, RF/anti-CCP positive, spares DIP, no enthesitis/dactylitis)
- Ankylosing spondylitis / axial SpA (axial without psoriasis/nail disease)
- Reactive arthritis (post-infective, similar SpA features)
- Gout (first MTP, tophi, crystals — can coexist; psoriasis raises urate)
- Osteoarthritis of DIP (Heberden nodes, no inflammation/nail pits)
Investigations
- RF and anti-CCP (usually negative — supports seronegative SpA)
- ESR/CRP (may be normal despite active disease)
- X-rays: 'pencil-in-cup' deformity, DIP erosions with new bone, fluffy periostitis, asymmetric sacroiliitis
- HLA-B27 (axial/enthesitis phenotype)
- Ultrasound/MRI for enthesitis, synovitis, early sacroiliitis
- Skin/nail exam (hidden psoriasis: scalp, umbilicus, natal cleft, nails); uric acid to exclude gout
Management
- Confirm diagnosis (CASPAR criteria: inflammatory articular disease + psoriasis/history/nail changes + negative RF + dactylitis + juxta-articular new bone)
- Identify active domains (peripheral, axial, enthesitis, dactylitis, skin, nails) — treatment is domain-driven
- Mild peripheral/monoarthritis: NSAIDs +/- intra-articular steroid; start csDMARD early if persistent/polyarticular
- Peripheral polyarthritis: csDMARD (methotrexate first; leflunomide/sulfasalazine alternatives) — also treats skin
- Inadequate response or poor prognosis (erosions, high activity): escalate to biologic — TNF inhibitor, IL-17 inhibitor, or IL-23/IL-12-23 inhibitor; or JAK inhibitor; or PDE4 inhibitor (apremilast) for milder disease
- Axial-predominant disease: csDMARDs ineffective for spine — go to NSAIDs then biologic (TNFi or IL-17i; avoid IL-23i for pure axial)
- Predominant enthesitis/dactylitis: TNFi, IL-17i, IL-23i, JAKi or apremilast (csDMARDs less effective for enthesitis)
- Co-manage skin psoriasis with dermatology; screen and manage cardiometabolic comorbidity (obesity, metabolic syndrome, uveitis, IBD)
Drugs & doses
Disposition
Complications & pitfalls
- Erosive joint damage, arthritis mutilans, functional disability
- Uveitis, inflammatory bowel disease association
- Increased cardiovascular and metabolic syndrome risk
- Axial ankylosis and reduced spinal mobility
- Psychological burden of combined skin + joint disease
Exam pearls
- GRAPPA/EULAR 2021-2023: treatment is domain-based — csDMARDs work for peripheral arthritis but NOT for axial disease or enthesitis, where biologics are needed.
- Choose biologic by comorbidity: IL-17i excellent for skin but avoid in active IBD; IL-23i strong for skin not for pure axial disease.
- Always examine nails and hidden sites (scalp, natal cleft, umbilicus) — psoriasis may be subtle and is the diagnostic clue.
- Dactylitis and enthesitis are hallmark SpA features distinguishing PsA from RA.
- Screen for and treat cardiometabolic risk and depression — major comorbidities.
- JAK inhibitor caution mirrors RA (age >65, smoker, prior MACE/VTE/malignancy).
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.